Compounded semaglutide vs Ozempic, and compounded tirzepatide vs Zepbound
The short answer
Compounded semaglutide vs Ozempic starts with approval: compounded semaglutide is not FDA-approved, and FDA says a compounded drug is not a generic. Ozempic, Wegovy, Zepbound and Mounjaro went through FDA approval. Compounded versions are not reviewed for safety, effectiveness or quality before they are sold. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025.
Key takeaways
- Compounded semaglutide and tirzepatide are not FDA-approved, and FDA says a compounded drug is not a generic.
- FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
- Concentrations vary. Ask your prescriber or pharmacist for your vial's strength and your dose in mg and in mL.
- FDA determined both injection shortages resolved. It says it then generally considers a drug commercially available, which brings back the limits on compounding copies.
- If you use a compounded product, this page is not a reason to stop or change anything on your own. Take your questions to your prescriber or pharmacist.
On this page
- Which products are FDA-approved?
- What does FDA review, and what does it not?
- How do the form and the dosing differ?
- Are the brand-name drugs still on the shortage list?
- What do the adverse event reports show?
- What are sellers not allowed to claim?
- How do the brand-name self-pay prices compare?
- If you are using a compounded product
- Frequently asked questions
- Sources
People compare compounded semaglutide with Ozempic and Wegovy, and compounded tirzepatide with Zepbound and Mounjaro, because the names of the ingredients match. FDA treats them as different things. This page sets out the differences that FDA and the product labels describe: approval, review, form and dosing, shortage status, adverse event reporting, and price.
We do not sell, recommend, rank or link to any seller of compounded products, and this page carries no offers and no prices for them. It’s part of our compounded GLP-1 guide.
Which products are FDA-approved?
The brand-name medicines are. The FDA-approved medicines containing semaglutide are Ozempic, Wegovy and Rybelsus. The FDA-approved medicines containing tirzepatide are Zepbound and Mounjaro. Each has its own label, its own approved uses and its own dose schedule.
Compounded versions are not approved. FDA’s wording: “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
A compounded drug is not a generic either. FDA explains that a generic is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act and must meet its requirements, including establishing therapeutic equivalence to a brand-name drug, while a compounded drug is not approved by FDA.
What does FDA review, and what does it not?
For an approved medicine, FDA says consumers and health care professionals rely on its drug approval process for verification of safety, effectiveness and quality. The label you read for Ozempic or Zepbound is part of that approval.
For a compounded product, none of that review happens before sale. What exists instead is oversight of the place that made it, and that depends on the kind of compounder:
- State-licensed pharmacies and physicians (section 503A). State boards of pharmacy have primary responsibility for day-to-day oversight, although FDA conducts surveillance and for-cause inspections. Drugs compounded under section 503A are not subject to current good manufacturing practice requirements.
- Outsourcing facilities (section 503B). These register with FDA, are inspected by FDA on a risk-based schedule and must meet current good manufacturing practice requirements.
Oversight of a facility is not approval of a product. FDA tells telehealth companies not to claim a compounded drug comes from an FDA-approved or FDA-licensed pharmacy, because “FDA does not approve or license any facility.” The 503A and 503B page explains the two categories.
FDA has also raised a question about the ingredient itself. It is aware that some semaglutide products sold by compounders may be salt forms, including semaglutide sodium and semaglutide acetate. FDA says these are different active ingredients than are used in the approved drugs, that it has no information on whether they have the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding.
How do the form and the dosing differ?
This is the most practical difference, and the one behind FDA’s dosing error alerts.
Brand-name injections are measured for you. FDA says the approved injectable semaglutide products are dosed in milligrams and have standard concentrations, and in its 2024 alert it said they were available only in pre-filled pens. Zepbound and Mounjaro come in pens and also in vials, and the vial labels say which syringe to use: one appropriate for the dose, for example a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose.
Compounded products vary. FDA is aware that compounders offer semaglutide in various containers, including multiple-dose vials and prefilled syringes. Concentrations vary between compounders, and a single compounder may offer several. The instructions may give the dose in units, the volume of which may vary depending on the concentration, instead of milligrams or milliliters.
The result, in FDA’s reports: patients drawing from multiple-dose vials administered five to 20 times more than the intended dose, and some health care providers miscalculated when converting milligrams to units or milliliters. Some of the adverse events required hospitalization.
FDA has also received adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed in doses beyond the FDA-approved label. It says that could mean more product in a single dose, more frequent doses, or a faster titration schedule, meaning the dose goes up more quickly. The approved schedules are on our dosing guide.
If you draw a dose from any vial, the guide to reading a U-100 syringe explains how units, mL and mg relate. The semaglutide dosage calculator, the tirzepatide dosage calculator and the units to mg calculator do the arithmetic for the strength printed on your vial. They do not recommend a dose, and the dosing errors page says who to call if you think you took too much.
Are the brand-name drugs still on the shortage list?
No. Compounded GLP-1 products spread while the brand-name injections were in shortage, because the limits on compounding copies ease when an approved drug is on FDA’s drug shortage list.
FDA determined the tirzepatide injection shortage resolved on December 19, 2024, after a first determination on October 2, 2024. It determined the semaglutide injection shortage resolved on February 21, 2025. The wind-down periods it gave compounders ended on February 18, 2025 and March 19, 2025 for tirzepatide, and on April 22, 2025 and May 22, 2025 for semaglutide.
FDA’s rule is that when a shortage is resolved, it generally considers the drug commercially available. Under section 503A a compounder may not, regularly or in inordinate amounts, make drugs that are essentially copies of a commercially available product. Outsourcing facilities may not compound from a bulk substance unless it is on the 503B bulks list or the drug is on the shortage list, and FDA has stated that tirzepatide and semaglutide appear on neither.
FDA’s general position has not changed through any of this: compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.
What do the adverse event reports show?
By May 31, 2026, FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
FDA attaches two cautions to those figures. They are likely underreported, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA. And it is not always possible to determine whether an event resulted directly from the drug or whether other factors contributed.
The brand-name medicines have side effects too, set out in their labels with the rates seen in trials. Our side effects guide reports those.
What are sellers not allowed to claim?
FDA has told companies that they cannot claim compounded products are generic versions of, or the same as, drugs approved by FDA, cannot state that compounded drugs share an active ingredient with the approved drugs, and cannot say compounded drugs are clinically proven to produce results. On March 3, 2026, it announced 30 warning letters to telehealth companies over claims implying sameness with FDA-approved products and branding that implied the telehealth firm was the compounder.
That’s why this site never describes a compounded product as equivalent to a brand, and it’s a reason to be careful with any website that does. The page on how to verify a pharmacy lists the checks FDA describes. FDA’s advice to patients is to get a prescription from their doctor and fill it at a state-licensed pharmacy.
How do the brand-name self-pay prices compare?
Cost is the usual reason people look at compounded products. So it’s worth knowing what the approved medicines cost through the manufacturers’ own cash programs, with a prescription and no insurance:
- Wegovy: the pill starts at $149 a month, and the pen is $349 a month for 0.25 mg through 2.4 mg after the new-patient offer.
- Ozempic: $349 a month for 0.25 mg, 0.5 mg or 1 mg through NovoCare.
- Zepbound: vials and the KwikPen start at $299 a month through LillyDirect and cost $449 at 7.5 mg to 15 mg when you buy each refill within 45 days of getting the last one.
- Mounjaro: $499 a month at every strength through LillyDirect.
Those are well below the list prices, which run from $1,027.51 per Ozempic pen to $1,349.02 per Wegovy package. The without-insurance guide ranks the cash routes, the cost guide covers insurance and savings cards, and the cost calculator prices a full year.
If you are using a compounded product
This page is not a reason to stop or change anything on your own. Take it to your prescriber or pharmacist, with questions such as these:
- What is the strength of my vial in mg per mL, and what is my dose in mg and in mL?
- Which pharmacy made the product, and is it licensed in my state?
- Is the dose I have been given within the FDA-approved label for the brand-name medicine?
- Would an FDA-approved medicine meet my needs, and what would it cost me?
Decisions about any medicine belong with you and a licensed prescriber.
Frequently asked questions
Is compounded semaglutide the same medicine as Ozempic?
FDA does not treat it as one. Ozempic is an FDA-approved medicine with its own label. A compounded product is not FDA-approved, and FDA says companies cannot claim that compounded products are generic versions of, or the same as, drugs approved by FDA. FDA also says some compounded semaglutide may be salt forms, which are different active ingredients than are used in the approved drugs.
Is compounded tirzepatide FDA-approved like Zepbound?
No. Zepbound and Mounjaro are the FDA-approved medicines containing tirzepatide. FDA states that compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed. By May 31, 2026, FDA had received more than 730 reports of adverse events (health problems reported after use) associated with compounded tirzepatide.
Is compounded semaglutide a generic?
No. FDA says a generic drug is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act and must establish therapeutic equivalence to a brand-name drug, while a compounded drug is not approved by FDA. Describing a compounded drug as a generic version of an approved drug is on FDA's list of false or misleading claims.
Why are compounded GLP-1 doses given in units instead of mg?
FDA says the instructions with compounded semaglutide may tell users to inject in units, the volume of which may vary depending on the concentration. It also says concentrations vary between compounders. FDA-approved injectable semaglutide is dosed in milligrams with standard concentrations. FDA received reports of patients taking five to 20 times the intended dose from multiple-dose vials.
Are semaglutide and tirzepatide still in shortage?
No, according to FDA. It determined the tirzepatide injection shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025. FDA says that when a shortage is resolved, it generally considers the drug commercially available, which brings back the limits on compounding copies of it.
How much do Ozempic, Wegovy and Zepbound cost without insurance?
Through the manufacturers' self-pay programs, the Wegovy pill starts at $149 a month, Zepbound starts at $299, and Ozempic costs $349 a month for 0.25 mg, 0.5 mg or 1 mg. Those are cash prices with a prescription and no insurance. List prices are far higher, at $1,027.51 per Ozempic pen.
Sources (28)
- 1.FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
“The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe.”
- 2.FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (containers and concentrations)
“For example, FDA is aware that compounders offer semaglutide injectable products in various containers and packaging, including multiple-dose vials and prefilled syringes. Product concentrations also may vary depending on the compounder, and a single compounder may offer multiple concentrations of compounded semaglutide products.”
- 3.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“Additionally, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label. This could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule).”
- 4.FDA: Compounding and the FDA: Questions and Answers
“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Consumers and health care professionals rely on FDA’s drug approval process for verification of safety, effectiveness and quality.”
- 5.FDA: Compounding and the FDA: Questions and Answers
“No. A generic drug is approved by FDA under 505(j) of the FD&C Act and meets all of the requirements of that section (including establishing therapeutic equivalence to a brand name drug, among others), while a compounded drug is not approved by FDA.”
- 6.FDA: Compounding and the FDA: Questions and Answers
“Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Unnecessary use of compounded drugs may expose patients to potentially serious health risks. For example, poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient. This can lead to serious patient injury and death.”
- 7.FDA: Compounding and the FDA: Questions and Answers
“Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities. FDA does conduct surveillance and for-cause inspections of state-licensed pharmacies that are not registered as outsourcing facilities.”
- 8.FDA: Compounding and the FDA: Questions and Answers
“Outsourcing facilities are a category of compounders established in 2013 by the Drug Quality and Security Act. Outsourcing facilities are inspected by FDA according to a risk-based schedule and are subject to increased quality standards. [...] Facilities that register with FDA as outsourcing facilities under section 503B are primarily overseen by FDA and inspected by FDA according to a risk-based schedule.”
- 9.FDA: Compounding and the FDA: Questions and Answers
“Quality standards for compounded drugs differ depending on the setting where compounding occurs. Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A of the FD&C Act, are not.”
- 10.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“FDA re-evaluated its determination from October 2, 2024, on the status of the tirzepatide shortage. Today, FDA has issued a new decision determining the tirzepatide injection shortage is resolved. [...] For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing tirzepatide injections within 60 calendar days from today’s announcement, until February 18, 2025. For outsourcing facilities under section 503B compounding, distributing or dispensing tirzepatide injections within 90 calendar days from today’s announcement, until March 19, 2025.”
- 11.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand. [...] For a state-licensed pharmacy or physician compounding under section 503A of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved product within 60 calendar days from today’s announcement, until April 22, 2025. For outsourcing facilities under section 503B of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved drug product within 90 calendar days from today’s announcement, until May 22, 2025.”
- 12.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“Section 503A of the FD&C Act includes restrictions on compounding drugs that are essentially copies of a commercially available drug. When a drug shortage is resolved, FDA generally considers the drug to be commercially available. Certain amounts are permissible under the law as long as the compounding is not done “regularly or in inordinate amounts.” Section 503B of the FD&C Act restricts outsourcing facilities from making compounded drugs that are essentially a copy of one or more FDA-approved drugs. Among other things, this means the compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA’s drug shortage list.”
- 13.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“Under section 503A: The drug product is compounded for an individual patient based on receipt of a prescription. The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product.”
- 14.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“Outsourcing facilities are restricted from compounding drugs using bulk drug substances (or API) unless: the bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need, which is referred to as the 503B bulks list or the drug compounded from the bulk drug substance is on FDA’s drug shortage list at the time of compounding, distribution and dispensing. Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
- 15.FDA: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs
“The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient.”
- 16.FDA: FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
“The agency reminds telehealth companies not to market compounded GLP-1 drugs to consumers with false or misleading claims, including: using branding on their website that falsely or misleadingly implies the telehealth company is the compounder. describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA. Generic drugs are approved by FDA prior to marketing, while a compounded drug is not approved by FDA. claiming a compounded drug has been FDA-approved or has otherwise been evaluated for safety and effectiveness when they are not. Compounded drugs are not reviewed by the agency for safety, effectiveness or quality prior to marketing. describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug. claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA does not approve or license any facility.”
- 17.FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
“The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. [...] This is the second group of warning letters sent to telehealth firms since the agency launched in September a crackdown on misleading direct-to-consumer pharmaceutical advertisements. [...] Primary violations identified in the letters included making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder.”
- 18.FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported. [...] As of May 31, 2026, the FDA has received: 990 reports of adverse events associated with compounded semaglutide. more than 730 reports of adverse events associated with compounded tirzepatide. It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events.”
- 19.FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“The agency is aware that some semaglutide products sold by compounders may be the salt forms. These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding.”
- 20.FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug.”
- 21.FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy. [...] The agency urges consumers to be vigilant when purchasing drugs online and only purchase from state-licensed pharmacies.”
- 22.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 23.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 24.
- 25.
- 26.
- 27.
- 28.
Related pages
- Compounded semaglutide and tirzepatide: what they are and where the rules stand
- 503A vs 503B compounding: what the difference means for GLP-1 drugs
- Is my compounding pharmacy legitimate? The checks FDA and NABP describe
- How to read a U-100 syringe: units, mL and mg
- Cheapest GLP-1 without insurance: Wegovy, Zepbound and the rest
